Skip to content
value.today
Intercept Pharmaceuticals Inc. logo

Intercept Pharmaceuticals Inc.

Total raised
$30 M
1 round on record
Latest round
$30 M
Aug 2012
First round on record
Aug 2012
Today
Private
See the company page

Intercept Pharmaceuticals Inc. is listed today as Intercept Pharmaceuticals: market value, financials and filings are on its company page.

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Intercept Pharmaceuticals Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2012$30 MNo. 1$10 to $50 million

Intercept Pharmaceuticals Inc.: Raise no. 1, Aug 2012

Investors in this round

2 investors had bought by the notice of Sep 4, 2012: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Intercept Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$30 M of $50 M offered; $20 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Barbara E. Duncan · Executive Officer
  • David E. Shapiro · Executive Officer
  • Luciano E. Adorini · Executive Officer
  • Mark E. Pruzanski · Executive Officer, Director
  • Jonathan T. Silverstein · Director
  • Klaus T. Veltinger · Director
  • Lorenzo E. Tallarigo · Director
  • Nicole E. Williams · Director
  • Paolo E. Fundaro · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Barbara Duncan, Secretary and CFO. Source: SEC Form D and 1 amendment, newest notice filed Sep 4, 2012. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Intercept Pharmaceuticals Inc. chose not to state its revenue in its newest notice of a funding round (Sep 2012).

    SEC Form D · Sep 2012

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Sep 2012

That is all the official record says: Intercept Pharmaceuticals Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Intercept Pharmaceuticals Inc. are on record.

Investors#

3 named in official filings. Open an investor to see everything it has backed.

Investors in Intercept Pharmaceuticals Inc.
InvestorKindAmountRoundRoleSource
Orbimed Advisors LLCFund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2012)SEC Form 3
OrbiMed Capital GP IV LLCFund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2012)SEC Form 3
S.p.A. GenextraPersonnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2012)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 2 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Intercept Pharmaceuticals Inc.
NameRoleNamed in
Barbara E. DuncanExecutive officerSep 2012
David E. ShapiroExecutive officerSep 2012
Luciano E. AdoriniExecutive officerSep 2012
Mark E. PruzanskiExecutive officerSep 2012
Jonathan T. SilversteinDirectorSep 2012
Klaus T. VeltingerDirectorSep 2012
Lorenzo E. TallarigoDirectorSep 2012
Mark E. PruzanskiDirectorSep 2012
Nicole E. WilliamsDirectorSep 2012
Paolo E. FundaroDirectorSep 2012
Klaus T. VeitingerDirectorAug 2012

About

American biopharmaceutical company.